1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Drugs In Development, 2022, provides an overview of the Pontine Glioma (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Pontine Glioma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 2, 21, 17, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 6, 1 and 1 molecules, respectively.
Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pontine Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pontine Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pontine Glioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pontine Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pontine Glioma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pontine Glioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pontine Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Pontine Glioma - Overview
- Pontine Glioma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Pontine Glioma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Pontine Glioma - Companies Involved in Therapeutics Development
- Pontine Glioma - Drug Profiles
- 8H-9 - Drug Profile
- Product Description
- Mechanism Of Action
- abemaciclib - Drug Profile
- Product Description
- Mechanism Of Action
- ACT-001 - Drug Profile
- Product Description
- Mechanism Of Action
- Alocelyvir - Drug Profile
- Product Description
- Mechanism Of Action
- AMXT-1501 + eflornithine hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- BXQ-350 - Drug Profile
- Product Description
- Mechanism Of Action
- Cabometyx - Drug Profile
- Product Description
- Mechanism Of Action
- CBL-0137 - Drug Profile
- Product Description
- Mechanism Of Action
- Cellular Immunotherapy for Diffuse Intrinsic Pontine Glioma and Glioblastoma - Drug Profile
- Product Description
- Mechanism Of Action
- Cellular Immunotherapy for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Cellular Immunotherapy for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
- Product Description
- Mechanism Of Action
- Cellular Immunotherapy for Pontine Glioma - Drug Profile
- Product Description
- Mechanism Of Action
- cemiplimab - Drug Profile
- Product Description
- Mechanism Of Action
- cobimetinib fumarate - Drug Profile
- Product Description
- Mechanism Of Action
- disufenton sodium - Drug Profile
- Product Description
- Mechanism Of Action
- doxorubicin - Drug Profile
- Product Description
- Mechanism Of Action
- ensartinib hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- everolimus - Drug Profile
- Product Description
- Mechanism Of Action
- fimepinostat - Drug Profile
- Product Description
- Mechanism Of Action
- G2B-001 - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy for Diffuse Intrinsic Pontine Glioma - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Target B7H3 for CNS Tumor - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Target GD-2 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Target WT1 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- indoximod - Drug Profile
- Product Description
- Mechanism Of Action
- ipilimumab + nivolumab - Drug Profile
- Product Description
- Mechanism Of Action
- Kid EDV - Drug Profile
- Product Description
- Mechanism Of Action
- larotrectinib sulfate - Drug Profile
- Product Description
- Mechanism Of Action
- lenvatinib mesylate - Drug Profile
- Product Description
- Mechanism Of Action
- MANA-677679 - Drug Profile
- Product Description
- Mechanism Of Action
- marizomib - Drug Profile
- Product Description
- Mechanism Of Action
- MDNA-55 - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibody Conjugate to Target B7H3 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
- Product Description
- Mechanism Of Action
- nimotuzumab - Drug Profile
- Product Description
- Mechanism Of Action
- nivolumab - Drug Profile
- Product Description
- Mechanism Of Action
- omburtamab - Drug Profile
- Product Description
- Mechanism Of Action
- ONC-201 - Drug Profile
- Product Description
- Mechanism Of Action
- ORX-101 - Drug Profile
- Product Description
- Mechanism Of Action
- P-28 - Drug Profile
- Product Description
- Mechanism Of Action
- palbociclib - Drug Profile
- Product Description
- Mechanism Of Action
- panobinostat - Drug Profile
- Product Description
- Mechanism Of Action
- panobinostat SR - Drug Profile
- Product Description
- Mechanism Of Action
- paxalisib - Drug Profile
- Product Description
- Mechanism Of Action
- pomalidomide - Drug Profile
- Product Description
- Mechanism Of Action
- RG-2833 - Drug Profile
- Product Description
- Mechanism Of Action
- ribociclib succinate - Drug Profile
- Product Description
- Mechanism Of Action
- RNL - Drug Profile
- Product Description
- Mechanism Of Action
- S-588410 - Drug Profile
- Product Description
- Mechanism Of Action
- selinexor - Drug Profile
- Product Description
- Mechanism Of Action
- SL-701 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit ACVR1 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
- Product Description
- Mechanism Of Action
- sotigalimab - Drug Profile
- Product Description
- Mechanism Of Action
- SurVaxM - Drug Profile
- Product Description
- Mechanism Of Action
- tasadenoturev - Drug Profile
- Product Description
- Mechanism Of Action
- trabedersen - Drug Profile
- Product Description
- Mechanism Of Action
- unesbulin - Drug Profile
- Product Description
- Mechanism Of Action
- Vaccine for Glioma - Drug Profile
- Product Description
- Mechanism Of Action
- Vaccine for Pontine Glioma - Drug Profile
- Product Description
- Mechanism Of Action
- Vaccine to Target CMV Antigen for Central Nervous System Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- WP-1066 - Drug Profile
- Product Description
- Mechanism Of Action
- zotiraciclib citrate - Drug Profile
- Product Description
- Mechanism Of Action
- Pontine Glioma - Dormant Projects
- Pontine Glioma - Discontinued Products
- Pontine Glioma - Product Development Milestones
- Featured News & Press Releases
- Nov 20, 2022: Oncotelic prresenting data for OT101 against diffuse intrinsic pontine glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
- Oct 06, 2022: PNOC clinical study of kazia's paxalisib in childhood brain cancer expands internationally
- Jun 21, 2022: Orphan Designation granted by EMA to MTX110 development for the treatment of Glioma
- Jun 15, 2022: Midatech Pharma : An update to MTX110 study in pediatric patients with DIPG to be presented at The International Symposium on Pediatric Neuro-Oncology, Hamburg, Germany (ISPNO 2022)
- Nov 22, 2021: DNAtrix announces oral presentation of positive overall survival data with DNX-2401 in DIPG at the Society for Neuro-oncology (SNO) annual meeting
- Aug 13, 2021: Plus Therapeutics to present data from ReSPECT-GBM trial at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting
- Jul 19, 2021: Oblato announces that it has received a positive response from the FDA for the use of OKN-007 for patients with high-grade gliomas in an expanded access program
- Jul 07, 2021: The new immunomodulator ACT001 shows great potential
- Apr 29, 2021: Y-mAbs announces Omburtamab data to be presented at 2021 ASCO annual meeting
- Mar 25, 2021: Midatech Pharma announces MTX110 update & headline results for 2020
- Mar 03, 2021: Oblato announces Fast Track Designation of OKN-007 for diffuse intrinsic pontine glioma from the FDA
- Dec 11, 2020: Midatech Pharma announces MTX110 Ppogrammes to be presented at ISPNO 2020
- Dec 10, 2020: Oblato announces discussion outcome with FDA for development of OKN-007 for diffuse intrinsic pontine glioma
- Dec 10, 2020: Kazia to collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for new Paxalisib combination study in DIPG
- Dec 01, 2020: Moleculin announces FDA approves 3 rare pediatric disease designations for WP1066
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Pontine Glioma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pontine Glioma - Dormant Projects, 2022
- Pontine Glioma - Discontinued Products, 2022
- Number of Products under Development for Pontine Glioma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A. Menarini Industrie Farmaceutiche Riunite Srl
- Accendatech Co Ltd
- Aminex Therapeutics Inc
- Apexigen Inc
- Bayer AG
- Bexion Pharmaceuticals LLC
- BioMarin Pharmaceutical Inc
- Bionaut Labs Inc
- Bristol-Myers Squibb Co
- CDG Therapeutics Inc
- Chimerix Inc
- Cothera Bioscience Pty Ltd
- Curis Inc
- DNAtrix Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Gate2Brain SL
- ImmunityBio Inc
- Immunomic Therapeutics Inc
- Incuron
- InnoMab Pte Ltd
- Karyopharm Therapeutics Inc
- Kazia Therapeutics Ltd
- Lumos Pharma Inc
- M4K Pharma Inc
- Mana Therapeutics Inc
- Medicenna Therapeutics Corp
- Midatech Pharma Plc
- MimiVax LLC
- Moleculin Biotech Inc
- Novartis AG
- Oblato Inc
- OncoRx Pharmaceuticals Inc
- Oncotelic Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- Pfizer Inc
- Plus Therapeutics Inc
- PTC Therapeutics Inc
- Regeneron Pharmaceuticals Inc
- Secura Bio Inc
- Shionogi & Co Ltd
- TCR Cure Biopharma Technology Co Ltd
- Tmunity Therapeutics Inc
- Xcovery Holding Co LLC
- Y-mAbs Therapeutics Inc
